English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/156233
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

DC FieldValueLanguage
dc.contributor.authorMarco-Contelles, José-
dc.contributor.authorUnzeta, M.-
dc.contributor.authorBolea, Irene-
dc.contributor.authorEsteban, G.-
dc.contributor.authorRamsay, Rona R.-
dc.contributor.authorRomero, A.-
dc.contributor.authorMartínez-Murillo, Ricardo-
dc.contributor.authorCarreiras, M. Carmo-
dc.contributor.authorIsmaili, L.-
dc.date.accessioned2017-10-11T08:50:19Z-
dc.date.available2017-10-11T08:50:19Z-
dc.date.issued2016-
dc.identifierdoi: 10.3389/fnins.2016.00294-
dc.identifierissn: 1662-453X-
dc.identifier.citationFrontiers in Neuromorphic Engineering 10 (2016)-
dc.identifier.urihttp://hdl.handle.net/10261/156233-
dc.description.abstractThe complex nature of Alzheimer's disease (AD) has prompted the design of Multi-Target-Directed Ligands (MTDL) able to bind to diverse biochemical targets involved in the progress and development of the disease. In this context, we have designed a number of MTD propargylamines (MTDP) showing antioxidant, anti-beta-amyloid, anti-inflammatory, as well as cholinesterase and monoamine oxidase (MAO) inhibition capacities. Here, we describe these properties in the MTDL ASS234, our lead-compound ready to enter in pre-clinical studies for AD, as a new multipotent, permeable cholinesterase/monoamine oxidase inhibitor, able to inhibit Aß-aggregation, and possessing antioxidant and neuroprotective properties.-
dc.relationMU and JM thank MINECO (Spain) for support (Grant SAF2012-33304; SAF2015-65586-R). RR, MU, GE, and JM thank EU (COST Action 1103) for support.-
dc.rightsopenAccess-
dc.subjectmonoamine oxidases-
dc.subjectdrugs-
dc.subjectcholinesterases-
dc.subjectAlzheimer's disease-
dc.subjectmulti-target directed ligands-
dc.titleASS234, as a new multi-target directed propargylamine for Alzheimer's disease therapy-
dc.typeartículo-
dc.identifier.doi10.3389/fnins.2016.00294-
dc.date.updated2017-10-11T08:50:20Z-
dc.description.versionPeer Reviewed-
dc.language.rfc3066eng-
dc.relation.csic-
Appears in Collections:(IC) Artículos
Files in This Item:
File Description SizeFormat 
Frontiers in Neuroscience.pdf418,62 kBAdobe PDFThumbnail
View/Open
Show simple item record
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.